Live Analyst Rating Changes 4873 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Martin PhD
BB
David Martin PhD
Bloom Burton
Wall Street Analyst
★★★☆☆
#1560
on 13Foresight · ranked by our own returns
33%
Success Rate
-1.6%
Average Return
2 of 6 calls profitable · -8.9% vs benchmark
📈 Across the calls we could measure, roughly 33% of David Martin PhD's ratings turned a profit when each position was held for 1 year — averaging -1.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

53 Buy 4 Hold 0 Sell
David's Stock Coverage 17 ratings · 2026-07-03
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ZYME
Zymeworks
 Jun 29, 2026 BUY Strong Buy
+21.9% avg upside
25 analysts
$36.00
36.81% Upside
 +9.2%
TSE:MDP
Medexus Pharmaceuticals Inc
 Jun 29, 2026 BUY Strong Buy
+5.6% avg upside
5 analysts
$6.00
14.69% Upside
 ·
TSE:RX
Biosyent
 Jun 04, 2026 BUY Strong Buy
+24.6% avg upside
1 analyst
$18.00
24.62% Upside
 ·
TSE:HLS
HLS Therapeutics Inc
 May 19, 2026 BUY Strong Buy
+111.5% avg upside
4 analysts
$12.00
182.38% Upside
 ·
TSE:MBX
Microbix Biosystms
 May 15, 2026 BUY Strong Buy
+33.3% avg upside
1 analyst
$0.40
33.32% Upside
 ·
AUPH
Aurinia Pharmaceuticals
 May 11, 2026 HOLD Strong Buy
-2.4% avg upside
12 analysts
$15.00
3.85% Downside
 -0.7%
TSE:CRRX
CareRx
 May 08, 2026 BUY Strong Buy
+55.2% avg upside
5 analysts
$5.00
43.74% Upside
 ·
TSE:GUD
Knight Therapeutics
 May 08, 2026 BUY Strong Buy
-15.7% avg upside
7 analysts
$12.00
21.95% Upside
 ·
TSE:EPRX
Eupraxia Pharmaceuticals
 Apr 27, 2026 BUY Strong Buy
+140.6% avg upside
9 analysts
$19.90
110.65% Upside
 ·
AU:PYC
PYC Therapeutics Limited
 Mar 19, 2026 BUY Strong Buy
+120.9% avg upside
3 analysts
$5.00
217.39% Upside
 ·
XENE
Xenon
 Mar 09, 2026 BUY Strong Buy
+3.4% avg upside
28 analysts
$74.00
21.39% Upside
 -3.8%
HELP
Helus Pharma
 Mar 05, 2026 BUY Strong Buy
+613.9% avg upside
12 analysts
$47.00
653.26% Upside
 ·
TSE:MDNA
Medicenna Therapeutics Corp
 Dec 11, 2025 BUY Strong Buy
+1247.6% avg upside
9 analysts
$4.00
952.58% Upside
 ·
ABCL
AbCellera Biologics
 Nov 19, 2025 BUY Strong Buy
+63.1% avg upside
15 analysts
$9.00
10.91% Upside
 +22.1%
VRDN
Viridian Therapeutics
 Oct 21, 2025 BUY Strong Buy
+81.7% avg upside
32 analysts
$13.86
28.64% Downside
 -20.9%
TSE:DHT.UN
DRI Healthcare
 Jul 18, 2025 BUY Strong Buy
+5.6% avg upside
6 analysts
$19.00
0.54% Upside
 ·
TSE:CNVI
Conavi Medical
 Jul 06, 2025 BUY Buy
+580.1% avg upside
4 analysts
$1.00
334.83% Upside
 ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Martin PhD — Frequently Asked Questions
How accurate are David Martin PhD's stock ratings?
Based on the calls 13Foresight could measure, about 33% of David's ratings were profitable over a one-year hold, with an average return of -1.6% per rating, or -8.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is David ranked on 13Foresight?
David Martin PhD is currently ranked #1560 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on ZYME, TSE:MDP, TSE:RX, TSE:HLS, TSE:MBX, AUPH, TSE:CRRX, TSE:GUD, TSE:EPRX, AU:PYC, XENE, HELP and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.